Price
$13.66
Decreased by -1.09%
Dollar Volume (20D)
1.02 M
ADR%
8.4
Earnings Report Date (estimate)
Nov 8, 23 (-0.8)
Market Cap.
405.79 M
Shares Float
11.61 M
Shares Outstanding
29.71 M
Beta
0.00
Price / Earnings
-4.16
BPR
1.09
20D Range
12.80 16.28
50D Range
7.58 16.28
200D Range
4.87 16.28
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 10, 23 0.81
Increased by +252.83%
0.85
Decreased by -4.71%
May 11, 23 -0.79
Increased by +73.49%
-0.68
Decreased by -16.18%
Mar 29, 23 -0.61 -0.63
Increased by +3.17%
Nov 9, 22 -0.59 -0.59
Aug 11, 22 -0.53 -0.46
Decreased by -15.22%
May 10, 22 -2.98 -0.52
Decreased by -473.08%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 0.00
Decreased by N/A%
-15.80 M
Decreased by -63.28%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-14.61 M
Decreased by -92.20%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-12.79 M
Decreased by -84.17%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-10.91 M
Decreased by -117.86%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-9.68 M
Decreased by -372.61%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00 - -7.60 M -
Decreased by N/A%
-
Sep 30, 21 0.00 - -6.94 M -
Decreased by N/A%
-
Jun 30, 21 0.00 - -5.01 M -
Decreased by N/A%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.